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ABSTRACT
Introduction: Residual pain is a major factor in
patient dissatisfaction following total hip arthroplasty or
total knee arthroplasty (THA/TKA). The proportion of
patients with unfavourable long-term residual pain is
high, ranging from 7% to 34%. There are studies
indicating that a preoperative degree of central
sensitisation (CS) is associated with poorer
postoperative outcomes and residual pain. It is thus
hypothesised that preoperative treatment of CS could
enhance postoperative outcomes. Duloxetine has been
shown to be effective for several chronic pain
syndromes, including knee osteoarthritis (OA), in
which CS is most likely one of the underlying pain
mechanisms. This study aims to evaluate the
postoperative effects of preoperative screening and
targeted duloxetine treatment of CS on residual pain
compared with care-as-usual.
Methods and analysis: This multicentre,
pragmatic, prospective, open-label, randomised
controlled trial includes patients with idiopathic hip/
knee OA who are on a waiting list for primary THA/
TKA. Patients at risk for CS will be randomly
allocated to the preoperative duloxetine treatment
programme group or the care-as-usual control
group. The primary end point is the degree of
postoperative pain 6 months after THA/TKA.
Secondary end points at multiple time points up to
12 months postoperatively are: pain, neuropathic
pain-like symptoms, (pain) sensitisation, pain
catastrophising, joint-associated problems, physical
activity, health-related quality of life, depressive and
anxiety symptoms, and perceived improvement. Data
will be analysed on an intention-to-treat basis.
Ethics and dissemination: The study is approved
by the local Medical Ethics Committee (METc 2014/
087) and will be conducted according to the
principles of the Declaration of Helsinki (64th,
2013) and the Good Clinical Practice standard
(GCP), and in compliance with the Medical
Research Involving Human Subjects Act (WMO).
Trial registration number: 2013-004313-41; Pre-
results.
BACKGROUND AND RATIONALE
Total joint replacement (TJR) is considered
to be a safe, successful and cost-effective pro-
cedure for the treatment of advanced osteo-
arthritis (OA).1–3 Despite its success, the
overall incidence of dissatisfaction is high, as
7% of patients with total hip arthroplasty
(THA) and 20% of patients with total knee
arthroplasty (TKA) are dissatisfied 1 year
after arthroplasty.4 5 The main factors asso-
ciated with patient-perceived level of dissatis-
faction after TJR are level of residual pain,
functional outcome and accomplished level
of preoperative expectations.4–7 Of all factors,
residual pain seems to be the most promin-
ent cause of dissatisfaction.4 5 7 8 The propor-
tion of patients with unfavourable long-term
Strengths and limitations of this study
▪ This is the first randomised controlled trial to
assess preoperative as well as early and late
postoperative effects of a substantial preopera-
tively targeted duloxetine regimen.
▪ By using a pragmatic trial design involving a
care-as-usual control group, more insight will be
gained into the effectiveness of duloxetine, with
patient-centred end points focusing on everyday
relevancy.
▪ Owing to the pragmatic trial design, the direct
effect of the duloxetine substance cannot be
measured; instead, the effect of the total ‘tar-
geted treatment package’ is measured.
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residual pain is high, ranging from 7% to 23% after
THA and 10% to 34% after TKA.9
Over the past decades, it has become clear that OA
pain varies among patients with OA, from intermittent
to constant pain and from nociceptive to neuropathic
pain-(NP) like symptoms.10 These variations may be
explained by OA-induced changes in the biochemical
environment around peripheral joint nociceptors and
joint structures.11 It is thought that these changes could
lead to hyperexcitability of the peripheral (peripheral
sensitisation) and ultimately the central nervous system
(central sensitisation, CS).11–13 CS can be defined as an
‘increased responsiveness of nociceptive neurons in the
central nervous system’, ‘this may include increased
responsiveness due to dysfunction of endogenous pain
control systems’.13a In a subset of patients, it is hypothe-
sised that CS combined with peripheral articular nerve
disruption is accountable for, or at least associated with,
joint-related NP-like symptoms such as allodynia and
hyperalgesia, and other characteristics such as spontan-
eous pain, widespread pain, referred pain and temporal
summation.12–14
There are indications that preoperative signs/symptoms
suggesting CS are associated with poorer postoperative
outcomes and residual pain after TJR.15–17 Lundblad
et al16 found less favourable pain relief 18 months after
TKA in patients with preoperative features of possible CS
such as low pain thresholds at remote sites (secondary
hyperalgesia) and high preoperative visual analogue scale
(VAS) scores for pain at rest (spontaneous pain). Wylde
et al15 17 further showed that CS-associated features such
as multiple-site pain and preoperative pain sensitisation at
remote sites (secondary hyperalgesia) are independent
determinants of residual pain 12 and 18 months after
TKA. Hence, it is hypothesised that preoperative-targeted
treatment of CS could be beneficial towards decreasing
the level of residual postoperative pain.
There is preclinical18 19 and clinical evidence that
duloxetine, a centrally acting antidepressant, is effica-
cious in the treatment of chronic pain conditions in
which CS is most likely one of the prominent underlying
pain mechanisms, such as diabetic peripheral NP,20 21
fibromyalgia22 and chronic low back pain.23 The mech-
anism of pain inhibition is thought to be related to the
amelioration of serotonin and norepinephrine activity in
the central nervous system.24 There is also preclinical25
and clinical evidence that duloxetine is beneficial for
lowering chronic knee OA pain compared with a
placebo.26–31 The observed knee OA pain relief was due
to a direct analgesic effect and not due to mood
improvement.
On the basis of the observed relationship between pre-
operative signs/symptoms indicating CS and negative
postoperative outcomes, this study aims to evaluate the
postoperative effects of preoperative-targeted duloxetine
treatment of CS on residual pain after THA/TKA com-
pared with care-as-usual. The primary objective is there-
fore to determine the effect of preoperative-targeted
duloxetine treatment on residual pain 6 months after
THA/TKA. The secondary objectives are to determine
the effect at different preoperative and postoperative
follow-up time points (table 1) on: pain, NP-like symp-
toms, (pain) sensitisation, pain catastrophising,
joint-associated problems, physical activity, health-related
quality of life, depressive and anxiety symptoms, per-
ceived improvement and arthroplasty-related
expectations.
METHODS AND DESIGN
This study is a multicentre (University Medical Center
Groningen (UMCG), Martini Hospital Groningen (MH)
and Medical Center Leeuwarden (MCL)), pragmatic,
open-label randomised controlled trial. After signing
informed consent, eligible patients will be randomly allo-
cated by means of a web-based system (ALEA,
FormsVision, Abcoude, the Netherlands) to an interven-
tion or a control group (figure 1). The intervention will
consist of 10 weeks of preoperative duloxetine treatment
(7 weeks on target dosage). This treatment period was
chosen on the basis of two large placebo-controlled ran-
domised control trials (RCTs) among patients with knee
OA which showed that the main pain-relieving effect of
duloxetine reached a plateau after 7 weeks on target
dosage.27 28 To reduce the risk of developing side
effects,32 the first week of treatment will be initiated with
half of the target dose (30 mg/day). In the second
week, there will be up-titration to the target dosage of
60 mg/day (2×30 mg/day capsule). The last two treat-
ment weeks (weeks 9 and 10) are a drug-tapering phase:
duloxetine dosage will be lowered to 30 mg/day to
reduce the risk of developing discontinuation symp-
toms.33 In the control group, participants will receive no
specific intervention and solely receive standard pre-
operative care-as-usual. However, in the perioperative
and early postoperative period usage of agents to
address specifically NP (like gabapentinoids) will be dis-
couraged (by communicating this with the anaesthesiol-
ogist that is responsible for the participants’ pain
management). Since, usage of these agents could poten-
tially interfere with the study outcome(s). As the current
waiting period for surgery is around 2–3 months, no sig-
nificant treatment delay is expected. For each partici-
pant, the duration of the clinical trial will be around
15 months, including baseline visit, a ±11-week preopera-
tive period and a 1-year postoperative follow-up period
(table 1, figure 1).
Patient selection and study population
When placed on the waiting list for THA/TKA, patients
will be asked to fill in a questionnaire about NP-like
symptoms (the modified-painDETECT questionnaire
(mPD-Q)34 34a). The mPD-Q is derived from the original
painDETECT questionnaire49 and is composed of seven
items evaluating pain quality, one item evaluating pain
pattern, and one item evaluating pain radiation. The
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Table 1 Schematic timeline
Enrolment
and
allocation Preoperative
Follow-up
(postoperative) General
Time point −T1 T0 T1 T2 T3 T4 T5 T6–7 Tx
Enrolment Arthroplasty
Eligibility screen
Informed consent
Allocation
Interventions
Duloxetine intervention
Assessment
Blood test*
Quantitative sensory testing (QST) † †
Questionnaires Outcomes
Modified-painDETECT
questionnaire (mPD-Q)
Assessing NP-like
symptoms and pain
(Numeric Rating Scale
(NRS) NRS: an aspect of
the mPD-Q)34a
The Hip disability/Knee
injury
and Osteoarthritis Outcome
Score (HOOS/KOOS)
Assessing joint-associated
problems and health-related
quality of life35 36
Visual Analogue Scale-pain
(VAS)
Assessing pain intensity37
Pain Catastrophising Scale
(PCS)
Assessing pain
catastrophising38–41
Patient Global Impression
of Improvement (PGI-I)
Assessing perceived
improvements42
International Physical
Activity
Questionnaire (IPAQ)
Assessing
physical activity43 44
RAND 36-item Health
Survey (RAND-36)
Assessing health-related
quality of life45
Hospital Anxiety and
Depression Scale (HADS)
Assessing depressive and
anxiety symptoms46
Hospital for Special
Surgery Knee/Hip
Replacement Expectations
survey (HSSKR/HSSHR)
Assessing
arthroplasty-related
expectations47 48
Adverse events
*Blood test at T1 is only applicable to the duloxetine intervention group.
†Only applicable to the duloxetine intervention group.
−T1, screening; T0, baseline; T1, days 14–17; T2, days 56–60; T3, 0–2 days preoperative; T4, days 2–3 postoperative; T5, weeks 5–7 postoperative; T6–7, 6 and 12 months postoperative
±2 weeks; Tx, no specific time point.
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score result is an aggregated score ranging from −1 to
38 points.49 Patients who are experiencing a possible or
likely NP phenotype (mPD-Q score >12 points) and who
are willing to consider participation will receive written
information about the study. After about 2 weeks, the
researchers will call the patients to ask if they have any
questions regarding the study; if patients are willing to
participate, they will be checked for inclusion and exclu-
sion criteria (TB and WR).
Inclusion criteria
To be eligible to participate in this study, a patient must be
an adult (age >18 years) diagnosed with primary hip/knee
OA (based on clinical and radiological American College
of Rheumatology (ACR) criteria) and having a possible or
likely NP phenotype (mPD-Q score >12) at the time of
screening. The latter criterion is included to identify
patients who are most likely more at risk for developing
residual pain, as research showed that characteristics of CS
are more prevalent in patients with hip/knee OA with a
possible or likely NP phenotype.50 51 On the basis of previ-
ous research, we anticipate that about 20–40% of the
patients who will be screened experience a possible or
likely NP phenotype.34 51–54
Exclusion criteria
Candidates who meet any of the following criteria will
be excluded from participation:
General exclusion criteria:
▸ Surgical hip or knee joint procedures performed in
the past yeari;
▸ Intra-articular knee/hip injection or knee/hip arth-
roscopy in the past 3 monthsi;
▸ Cognitive and/or neurological disorders that could
interfere strongly with questionnaire surveys (eg,
dementia)ii;
▸ An unstable and/or severely ill patient who is likely
to be hospitalised during the course of the study
or the illness compromises study participation
significantlyii;
▸ Planned or intended THA or TKA procedure within
the study duration (current planned arthroplasty not
included)iii;
▸ A history of significant peripheral nerve injuryiv;
▸ Previous exposure to duloxetinev.
Duloxetine-related exclusion criteria:
▸ Allergy to the duloxetine capsule (or another sero-
tonin-norepinephrine reuptake inhibitors s (SNRI));
▸ Usage of non-selective monoamine oxidase (MAO)
inhibitors, tricyclic antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs) or SNRIs in the
past year;
▸ Usage of strong cytochrome P450 1A2 (CYP1A2)
inhibitors;
▸ History of peptic ulcer disease or bleeding disorder
(or another substantial risk factor for bleeding, such
as usage of coumarin derivatives);
▸ Impaired liver function (alanine aminotransferase
(ALAT) or aspartate aminotransferase (ASAT)
>100 IU/L or elevated prothrombin time (inter-
national normalised ratio) >1.5), or known liver cir-
rhosis or liver transplantation;
▸ Severe renal impairment (creatinine clearance–esti-
mated glomerular filtration rate <30 mL/min), previ-
ous renal transplantation or under renal dialysis;
▸ Psychiatric disorders, severe depression/major
depressive disorder (based on Hospital Anxiety and
Figure 1 Schematic scheme: preoperative period, ±11-week including 10 weeks of duloxetine and a preoperative
duloxetine-free period; follow-up period, postoperative up to 1 year; ‘initiation’, 2-week period, first week: 30 mg/day duloxetine,
second week: 60 mg/day duloxetine; ‘treatment phase’, 6-week period, 60 mg/day duloxetine; ‘taper’, 2-week period, 30 mg/day
duloxetine; TJR, total joint replacement (arthroplasty).
[i]This factor likely interferes significantly with the baseline measure.
[ii]This factor likely interferes significantly with participating
adequately in a randomised controlled trail with multiple time points.
[iii]This factor significantly influences multiple postoperative outcome
measures.
[iv]This factor will probably influence pain quality in the lower
extremities.
[v]This factor likely influences the patient’s expectations of the
duloxetine treatment.
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Depression Scale (HADS) score >15 on the depres-
sion subscale)vi;
▸ A history of alcohol or other substance abuse (exclud-
ing nicotine and caffeine) or dependence within the
5 years prior to enrolment;
▸ History of cardiac arrhythmias, cardiac failure, myo-
cardial infarction or irregular heartbeat at baseline
(by checking radial pulse rhythm);
▸ Hyponatraemia (<135 mmol/L) or a history of fre-
quent hyponatraemias;
▸ History of uncontrolled hypertension, blood pressure
>180 mm Hg systolic or >110 mm Hg diastolic at
baseline;
▸ History of glaucoma (or increased intraocular pres-
sure), uncontrolled thyroid disease or history of
uncontrolled seizures;
▸ Currently pregnant or lactating, or planning to
become pregnant within the study period (self-
assessed), unwillingness to comply with reproductive
precautions; women who could become pregnant
must be willing to comply with approved birth control
measures.
Study procedures
Preoperative period
Baseline (T0)
Patients will visit the researcher of the outpatient clinic
of their own hospital to screen for the following exclu-
sion criteria: severe depression (based on HADS score
>15 on the depression subscale), uncontrolled hyperten-
sion, hyponatraemia, impaired liver or renal function
and pregnancy (applicable to women with childbearing
potential; hCG-urine dipstick and, when screened posi-
tive, hCG will be obtained in serum). If all of the inclu-
sion criteria and none of the exclusion criteria are
fulfilled, informed consent will be obtained and ran-
domisation will follow. Randomisation in the web-based
system will be executed by the local researcher (3 site-
specific researchers). A stratification factor will be the
type of arthroplasty (hip/knee). After randomisation,
there is a baseline assessment, including patient
characteristics and baseline values for outcome measures
(see table 1). This is thus a pragmatic trial, so no restric-
tions will be imposed on usage of escape (pain) medica-
tion or other medication. However, in the perioperative
and early postoperative period usage of agents to
address specifically NP (like gabapentinoids) will be dis-
couraged. Therefore local care-as-usual will be slightly
modified for participants in the MH and MCL, since
these two hospitals use gabapentinoids in the periopera-
tive and early postoperative period (in a subset of
patients).
Intervention group: ‘duloxetine’
Time point T0: medication period 1—‘initiation’
For safety reasons and to improve adherence, medica-
tion release takes place at three different time points.
Since the risk of side effects is higher at the beginning
of treatment, the first study period is relatively short
(2 weeks). Prior to medication release, the participant
will be informed and warned about possible side effects.
The participant will also receive a chart to record usage
and side effects. This chart will be collected at every sub-
sequent preoperative visit.
Time point T1: medication period 2—‘treatment phase’
This time point follows after 2 weeks of usage.
Participants will visit the outpatient clinic of their hos-
pital and will receive a limited set of pain-related ques-
tionnaires (table 1), which they have to fill in prior to
the visit. The visit will further consist of sensitisation
measurements (quantitative sensory testing, QST) fol-
lowed by duloxetine treatment evaluation. Drug account-
ability will be reported and any unused medication will
be collected, registered and destructed following local
protocol. Subsequently, duloxetine (60 mg/day) for the
following 6 weeks will be handed over. Serum sodium
level will be obtained once more to monitor for
duloxetine-induced hyponatraemia, a complication that
can occur early on after duloxetine initiation.56 57
Time point T2: medication period 3—‘taper phase’
This time point is defined as 8 weeks after duloxetine
initiation and marks the beginning of the drug-tapering
phase. This visit is identically structured as the previous
mentioned time point T1. Medication (duloxetine
30 mg/day) for the final two treatment weeks will be
handed over. Explicit warning will be given about dis-
continuation symptoms.
Time point T3: preoperative status
Participants will receive the full set of questionnaires by
mail (see table 1), which they have to fill in the day
before surgery. The questionnaires will be collected on
the day of admission to the hospital. At the moment of
collection, sensitisation measurements (QST) will be
performed (see table 1). Since concomitant usage of
non-steroidal anti-inflammatory drugs (NSAIDs) and
SNRIs is associated with diminished platelet function
and therefore with perioperative bleeding,58 surgery will
be performed a minimal 4 days after last duloxetine
usage (arthroplasty window, days 5–8).
Control group: ‘care-as-usual’
Time points T1, T2, T3
Time points T1 and T2 are defined as 2 weeks and
8 weeks after baseline (T0), respectively. Participants will
receive a set of questionnaires at both time points (see
table 1) by mail, which they have to fill in. After comple-
tion, they are asked to send them back by mail. Time point
T3 is identical to time point T3 of the intervention group.
[vi]Major depressive disorder is an exclusion criterion, since it is
associated with an increased risk of suicide in the early stages of
depression treatment by duloxetine.55
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Follow-up
Follow-up procedures will be identical for both study
groups (see figure 1). Time points T4 and T5, 2 days
and 6 weeks postoperatively, consist of limited sets of
pain-related questionnaires (see table 1). At T4, ques-
tionnaires will be collected at the ward, and at T5 at the
outpatient clinic during the regular appointment with
their orthopaedic surgeon. When collection at the hos-
pital is not possible, the participant will receive the set
of questionnaires by mail, to be filled in and sent back.
Time points T6 and T7, 6 and 12 months postopera-
tively, will consist of the full set of questionnaires (see
table 1), which participants will receive by mail and have
to send back.
Criteria for withdrawal
Participants have the right to withdraw at any point
during treatment without prejudice. The investigator or
regulatory authority can discontinue a participant’s par-
ticipation in the trial at any time if medically or other-
wise necessary. It is not advisable to discontinue
duloxetine treatment abruptly, especially when taking
60 mg/day. A participant who wishes to discontinue must
contact the investigator to obtain discontinuation advice.
Adverse events (AEs) and data safety monitoring
All AEs reported spontaneously by the participant or
observed by the investigators or staff will be recorded. In
case of a serious AE (SAE), the sponsor will report the
SAE to the accredited medical ethics committee. Since
every participant will undergo elective total hip or knee
arthroplasty (THA/TKA), this potential SAE will not be
seen as an SAE and this procedure and the related hospi-
talisation will not be reported as an SAE. However, pro-
longed hospitalisation (>14 days) will be reported as an
SAE. Rehospitalisation (for any reason) will also be
reported and handled as an SAE. Suspected unexpected
serious adverse reactions (SUSARs) will be reported to
the medical ethics committee and all AEs will be followed
until they are gone, or until a stable situation has been
achieved. The sponsor decided (approved by the medical
ethics committee) that, on the basis of the standards set
by national regulations (Nederlandse Federatie van
Universitair Medische Centra (NFU) standards59), no
Data and Safety Monitoring Board (DSMB) will be
installed, as the risk profile of duloxetine is well known
and duloxetine is already registered as an analgesic agent
in the USA by the Food and Drug Administration (FDA)
for use within patients with OA.55 However, if more than
one SUSAR is observed, contact will be sought with the
medical ethics committee to re-evaluate the study. No
additional participants will be included during the
re-evaluation period. The conduct and management will
be monitored by an independent trained and educated
monitor. On the basis of the negligible risk profile,
minimal monitoring is required (according to the NFU
standards59: one site visit per year).
Outcome measures
The following characteristics will be retrieved from
patient questionnaires, physical examination, the hos-
pital information system or medical records:
Patient characteristics
Gender, age, patient-reported height (cm) and weight
(kg), family status, highest reached level of education,
duration of OA pain symptoms, American Society of
Anesthesiologists classification, Kellgren-Lawrence grade,
previous joint procedures or injury, number of painful
joint/body regions, comorbidities, smoking and alcohol
consumption, and pain medication consumption.
Arthroplasty-related characteristics
Method of anaesthesia, type of arthroplasty, surgical
approach, postoperative analgesic consumption and
arthroplasty-related complications.
Safety parameters
(Severe) AEs, vital signs (blood pressure, pulse) and
clinical laboratory testing.
Primary outcome
Primary outcome is the amount of residual pain 6 months
after THA/TKA. The amount of (residual) pain will be
measured with the pain subscale of the Hip disability and
Osteoarthritis Outcome Score (HOOS) or the Knee
injury and Osteoarthritis Outcome Score (KOOS). These
Dutch questionnaires are proven to be valid and reli-
able.35 36 The key postoperative time point 6 months was
chosen as this is in practice considered as the first possible
time point to evaluate the ‘success’ of the arthroplasty.
Secondary outcomes
Secondary objectives are to determine the effect at dif-
ferent preoperative and postoperative follow-up time
points (see table 1) on pain, NP-like symptoms, pain
catastrophising, joint-associated problems, physical activ-
ity, health-related quality of life, depressive and anxiety
symptoms, perceived improvement and arthroplasty-
related expectations. These outcomes will be assessed
by means of several questionnaires at multiple follow-up
time points (see table 1). In addition to questionnaires,
QST will be performed at several preoperative time
points to assess pain and sensitisation. Two QST modal-
ities will be used: mechanical temporal summation
(MTS) and blunt pressure pain thresholds (PPTs).
Assessment will be performed at two locations, one
close to the affected hip/knee and one at a location
remote from the affected hip/knee (contralateral
forearm).60 These two QST modalities will be executed
by the local researcher. The researcher follows a stand-
ard operating procedure (SOP), based on the
DFNS-QST protocol.61 Multiple OA studies made use of
segments of this protocol (or nearly identical
procedures).50 51 62 63
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Mechanical temporal summation
MTS, a wind-up-like pain to repetitive non-invasive mech-
anical stimulation, is a clinical manifestation of central
integration and is believed to be a sensitive measure of
CS.63 64 The perceived intensity of a single pinprick
stimulus (Optihair2 von frey filament 256mN, Marstock
Nervtest, Germany) will be compared with that of a series
of 10 repetitive stimuli at the same physical intensity (1/s
applied within an area of 1 cm2). The entire procedure
will be repeated three times. The wind-up ratio is calcu-
lated as the ratio: mean rating of the three series divided
by the mean rating of the three single stimuli.
Blunt PPT
An algometer (Force Ten FDX 25 Digital force gage,
Wagner, instruments, Greenwich, CT, USA; 1 cm2 flat
rubber tip) will be used to quantify the pain threshold.
PPTs are proven to be highly reliable at painful, non-
painful and remote body sites.62 65 66 PPTs are considered
to be a reflection of peripheral sensitisation/nociceptive
processes at the site of the joint.60 At a remote site, it is
considered to reflect systemic altered pain processing/
CS.60 The PPTs at each site will be assessed three times
and the average of those measurements will be noted.
Handling and storage of data and documents
Personal data will be handled confidentially. Every par-
ticipant will receive a unique code; this code contains the
number of the hospital (UMCG/MH/MCL) followed by
a sequence number. Data of each participant will be col-
lected under this unique code. A unique participant
identification list will be used to link the data to the par-
ticipant. The key to the code is safeguarded by the prin-
cipal investigator. All source documents will be entered
in an electronic case report form (OpenClinica). The
retention period of the data and documents is 20 years.
Sample size
Sample-size calculation is performed with HOOS/KOOS
pain as the primary outcome measure. On the basis of a
previous OA study, the common SDs for the pain subscale
scores of the HOOS and KOOS are 17.7 and 17.2, respect-
ively.67 Since the smallest change score for the KOOS to be
considered clinically relevant is 10 points (on a 0–100
scale),68 power calculation is based on this difference. To
detect this difference with 80% power (two-sided signifi-
cance level of 0.05), a total of 47 participants is needed
per group. Taking into account the possibility of 20%
protocol violators and/or dropouts, inclusion of 59 partici-
pants per group is aimed for (total group: 118 partici-
pants). It is anticipated that this sample could be obtained
between October 2014 and the end of 2016.
Statistical considerations
All statistical analyses will be conducted by using the
IBM SPSS (V.22). Descriptive statistics will be used to
describe the demographic and baseline characteristics of
the participants. Continuous variables will be
summarised using means and SDs. Discrete variables will
be summarised by proportions and percentages.
For the primary end point, a Student’s t test (or a
non-parametric equivalent in case of a skewed distribu-
tion) will be used to determine possible differences in
pain on the KOOS/HOOS at 6 months postoperatively
between the two groups. Generalised Estimating
Equation (GEE) analysis will be used to determine pos-
sible differences in pain between the two groups over
time, adjusted for relevant covariates. For the secondary
end points, Student’s t tests (or a non-parametric equiva-
lent in case of a skewed distribution) will be used to
determine possible differences in secondary outcome
variables at multiple follow-up time points (see table 1)
between the two groups. GEE analyses will be used to
determine possible differences in secondary outcome
variables between the two groups over time, adjusted for
relevant covariates. All data analyses will be done on an
intention-to-treat basis. A p value of <0.05 is considered
statistically significant.
DISSEMINATION
This study will be conducted according to the principles
of the latest Declaration of Helsinki, the Medical
Research Involving Human Subjects Act (WMO) and
the Good Clinical Practice standard (GCP). The study is
investigator-initiated. No arrangements are made
between the subsidising party and the investigator con-
cerning publication of the research data. Independently
of the outcome, the results of the study will be published
in international peer-reviewed scientific journals. Patient
data will be presented anonymously in any publication
or scientific journal. All substantial amendments (modi-
fication to the protocol that is likely to affect the safety
or the scientific value of the trial) will be notified to the
local METc and to the competent authority Centrale
Commissie Mensgebonden Onderzoek (CCMO).
DISCUSSION
The Duloxetine in Osteoarthritis (DOA) study is, as far
as we know, the first pragmatic randomised controlled
clinical trial assessing the preoperative as well as the
early and late postoperative effects of a substantial
preoperative-targeted duloxetine regimen. To date, only
one study has assessed the early and late postoperative
effects of a single-dose or dual-dose perioperative dulox-
etine regimen in a TKA patient group.69 In this study,
no significant differences on pain scores were observed
up to 6 months postoperatively between two periopera-
tive 60 mg doses of duloxetine and placebo. Our study
differs significantly from this and other studies that
focus on diminishing the risk of residual pain. First, in
this study, only those patients will be included who are
probably at a higher risk for developing residual pain,
based on having a higher chance of experiencing pre-
operative CS. This entails a more tailored approach, as
we think not all OA patients are centrally sensitised and
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could benefit from a targeted preoperative treatment
package. Second, in general, previous studies on residual
postoperative pain are based on the theory70 71 that
surgery-induced tissue injury and acute postsurgical pain
probably result in CS and residual pain, whereas our
study is based on the theory that the preoperative CS
status induced by long-lasting OA is key and, as a conse-
quence, should be addressed preoperative instead of
perioperative/postoperative. Furthermore, we believe
that our chosen pragmatic trial design has validity to
assess the effects of the treatment regimen, as it mimics
real-life status with a care-as-usual control group as much
as possible. Moreover, the end points of this pragmatic
RCT are focused on the relevancy to everyday life, like
hip-specific and knee-specific pain, function and quality
of life. For these reasons, pragmatic randomised trials
are an increasingly popular design to test implementa-
tion interventions.72 Conversely, owing to the design
used, it will not be possible to analyse the direct effect of
the duloxetine substance but rather the effect of the
total targeted treatment package. Hence, this study is
powered for the effect measured in the total group; only
limited hip-specific/knee-specific conclusions can be
drawn. However, no significant group differences are
anticipated due to the shared underlying pain mechan-
ism. Knowledge gained from this study can potentially
improve postoperative pain relief and rehabilitation after
TJR. Moreover, owing to an extensive preoperative treat-
ment period, it could provide specific insight into the
effectiveness of duloxetine in patients with advanced hip
and knee OA with possible NP/CS.
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